This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Elanco's plans to acquire Bayer's animal health business faces further scrutiny in New Zealand

( May 8, 2020, 00:44 GMT | Official Statement) -- MLex Summary: A New Zealand review of US-based Elanco Animal Health's plans to acquire German pharmaceutical company Bayer's animal-health business is facing prolonged investigation by the country's competition watchdog. In a statement of issues published this week, the New Zealand Commerce Commission said in pushing back a decision on its review from April 21 to June 3, it is yet to conclude on the relevant markets for its review of the deal and is continuing to test the possible effects of the merger. The Commerce Commission is inviting Bayer and interested parties to make submissions to its review by May 21. The Commerce Commission's statement of issues is attached; the press release announcing the decision follows. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections